法尼醇X受体激动剂在非酒精性脂肪性肝炎治疗中的应用

沈镇扬; 蔡晓波; 陆伦根

doi:10.3969/j.issn.1001-5256.2022.06.038

法尼醇X受体激动剂在非酒精性脂肪性肝炎治疗中的应用

DOI: 10.3969/j.issn.1001-5256.2022.06.038

上海交通大学附属第一人民医院消化科，上海 200080

基金项目:

国家自然科学基金 (81970528)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：沈镇扬负责查阅文献，撰写文章；蔡晓波负责文献审核，修改文章；陆伦根负责拟定写作思路，指导撰写文章并最终定稿。

详细信息

通信作者:
陆伦根，lungenlu1965@163.com

计量
- 文章访问数: 689
- HTML全文浏览量: 128
- PDF下载量: 112
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-29
- 录用日期: 2021-11-29
- 出版日期: 2022-06-20

Application of farnesoid X receptor agonists in treatment of nonalcoholic steatohepatitis

Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China

Research funding:

National Natural Science Foundation of China (81970528)

More Information

Corresponding author: LU Lungen, lungenlu1965@163.com(ORCID: 0000-0002-1533-4068)

摘要

摘要: 非酒精性脂肪性肝炎(NASH)作为患病率较高的一种肝病，严重危害人类健康。近年来，法尼醇X受体相关药物在调节胆汁酸、糖脂代谢以及抑制炎症方面发挥了重要作用。总结了不同种类的法尼醇X受体激动剂在NASH治疗中的应用，为NASH的防治提供一定的依据。
- 非酒精性脂肪性肝炎 /
- 法尼醇X受体 /
- 药物疗法
Abstract: Nonalcoholic steatohepatitis (NASH) is a liver disease with a relatively high prevalence worldwide and greatly threatens human health. In recent years, farnesoid X receptor-related drugs have played an important role in regulating the metabolism of bile acid, glucose, and lipids and inhibiting inflammation. This article summarizes the application of farnesoid X receptor agonists in the treatment of NASH, so as to provide a basis for the prevention and treatment of NASH.
- Non-alcoholic Steatohepatitis /
- Farnesoid X Receptor /
- Drug Therapy

HTML全文

参考文献(34)

[1]	CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367.
[2]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312.
[3]	ALI AH, CAREY EJ, LINDOR KD. Recent advances in the development of farnesoid X receptor agonists[J]. Ann Transl Med, 2015, 3(1): 5. DOI: 10.3978/j.issn.2305-5839.2014.12.06.
[4]	CARR RM, REID AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease[J]. Curr Atheroscler Rep, 2015, 17(4): 500. DOI: 10.1007/s11883-015-0500-2.
[5]	YOUNOSSI ZM, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196. DOI: 10.1016/S0140-6736(19)33041-7.
[6]	SANYAL A, LOPEZ P, LAWITZ E, et al. SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR[J]. J Hepatol, 2019, 70(1): e796-e797. DOI: 10.1016/s0618-8278(19)31587-7.
[7]	KLUCHER K, WANG Y, HALCOMB R, et al. FRI-313-A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis[J]. J Hepatol, 2019, 70(1): e534. DOI: 10.1016/s0618-8278(19)31056-4.
[8]	FORMAN BM, GOODE E, CHEN J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites[J]. Cell, 1995, 81(5): 687-693. DOI: 10.1016/0092-8674(95)90530-8.
[9]	MAKISHIMA M, OKAMOTO AY, REPA JJ, et al. Identification of a nuclear receptor for bile acids[J]. Science, 1999, 284(5418): 1362-1365. DOI: 10.1126/science.284.5418.1362.
[10]	YANG ZX, SHEN W, SUN H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease[J]. Hepatol Int, 2010, 4(4): 741-748. DOI: 10.1007/s12072-010-9202-6.
[11]	DONG B, YOUNG M, LIU X, et al. Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters[J]. J Lipid Res, 2017, 58(2): 350-363. DOI: 10.1194/jlr.M070888.
[12]	MIYAZAKI T, HONDA A, IKEGAMI T, et al. Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model[J]. J Clin Biochem Nutr, 2019, 64(2): 112-123. DOI: 10.3164/jcbn.18-80.
[13]	KIR S, BEDDOW SA, SAMUEL VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis[J]. Science, 2011, 331(6024): 1621-1624. DOI: 10.1126/science.1198363.
[14]	WANG Y, NAKAJIMA T, GONZALEZ FJ, et al. PPARs as metabolic regulators in the liver: Lessons from liver-specific PPAR-null mice[J]. Int J Mol Sci, 2020, 21(6): 2061. DOI: 10.3390/ijms21062061.
[15]	PINEDA TORRA I, CLAUDEL T, DUVAL C, et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor[J]. Mol Endocrinol, 2003, 17(2): 259-272. DOI: 10.1210/me.2002-0120.
[16]	WANG YD, CHEN WD, WANG M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response[J]. Hepatology, 2008, 48(5): 1632-1643. DOI: 10.1002/hep.22519.
[17]	LI L, ZHANG Q, PENG J, et al. Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage[J]. Biochem Biophys Res Commun, 2015, 467(4): 841-846. DOI: 10.1016/j.bbrc.2015.10.056.
[18]	MOURIES J, BRESCIA P, SILVESTRI A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development[J]. J Hepatol, 2019, 71(6): 1216-1228. DOI: 10.1016/j.jhep.2019.08.005.
[19]	NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385(9972): 956-965. DOI: 10.1016/S0140-6736(14)61933-4.
[20]	AL-DURY S, WAHLSTRÖM A, PANZITT K, et al. Obeticholic acid may increase the risk of gallstone formation in susceptible patients[J]. J Hepatol, 2019, 71(5): 986-991. DOI: 10.1016/j.jhep.2019.06.011.
[21]	HERNANDEZ ED, ZHENG L, KIM Y, et al. Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents[J]. Hepatol Commun, 2019, 3(8): 1085-1097. DOI: 10.1002/hep4.1368.
[22]	GEGE C, HAMBRUCH E, HAMBRUCH N, et al. Nonsteroidal FXR ligands: Current status and clinical applications[J]. Handb Exp Pharmacol, 2019, 256: 167-205. DOI: 10.1007/164_2019_232.
[23]	PATEL K, HARRISON SA, ELKHASHAB M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial[J]. Hepatology, 2020, 72(1): 58-71. DOI: 10.1002/hep.31205.
[24]	LAWITZ E, GANE E, RUANE P, et al. SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2019, 70(1): e794. DOI: 10.1016/S0618-8278(19)31582-8.
[25]	GENIN MJ, BUENO AB, AGEJAS FRANCISCO J, et al. Discovery of 6-(4-{[5-Cyclopropyl-3-(2, 6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid: A novel FXR agonist for the treatment of dyslipidemia[J]. J Med Chem, 2015, 58(24): 9768-9772. DOI: 10.1021/acs.jmedchem.5b01161.
[26]	WANG Y, CRITTENDEN DB, ENG C, et al. Safety, pharmacokinetics, pharmacodynamics, and formulation of liver-distributed farnesoid X-receptor agonist TERN-101 in healthy volunteers[J]. Clin Pharmacol Drug Dev, 2021, 10(10): 1198-1208. DOI: 10.1002/cpdd.960.
[27]	CHAU M, LI Y, ROQUETA-RIVERA M, et al. Characterization of EDP-305, a highly potent and selective farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis[J]. Int J Gastroenterol, 2019, 3(1): 4-16. DOI: 10.11648/j.ijg.20190301.12.
[28]	AHMAD A, SANDERSON K, DICKERSON D, et al. Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects[J]. J Hepatol, 2018, 68: s584. DOI: 10.1016/s0168-8278(18)31427-2.
[29]	AN P, WEI G, HUANG P, et al. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction[J]. Liver Int, 2020, 40(7): 1655-1669. DOI: 10.1111/liv.14490.
[30]	WAGNER B, GOVEK S, NAGASAWA J, et al. Efficacy of MET409, a potent, novel non-bile acid FXR agonist, in rodents and cynomolgus monkeys[J]. Hepatology, 2017, 66(Suppl): 1049A.
[31]	WAGNER B, GOVEK S, NAGASAWA J, et al. MET409, a potent, non-bile acid sustained FXR agonist, shows rapid disease reversal in a diet-induced obese mouse model of biopsy-confirmed Nash[J]. Hepatology, 2018, 68(Suppl): 1006A.
[32]	HARRISON SA, BASHIR MR, SHIM-LOPEZ J, et al. MET409, a sustained FXR agonist, decreased hepatic fat and improved liver function without raising LDL-C after 28 days in NASH patients[J]. Hepatology, 2019, 70(Suppl): 1257A.
[33]	HARRISON SA, BASHIR MR, LEE KJ, et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2021, 75(1): 25-33. DOI: 10.1016/j.jhep.2021.01.047.
[34]	RADREAU P, JOLY S, DUBOS C, et al. In vitro and in vivo characterization of EYP001, a novel, potent and selective FXR agonist now in a Phase 2 clinical trial in NASH[J]. Hepatology, 2019, 70(Suppl): 1267A.